Key Highlights

  • Evotec issued a downward revision to its full-year 2026 outlook, now anticipating annual revenue between €570 million and €610 million.
  • The company's revised adjusted EBITDA guidance ranges from a loss of €70 million to a loss of €105 million, reflecting performance well below previous market expectations.
  • The guidance cut accompanies preliminary first-half 2026 results showing revenue of €300.1 million and a first-half adjusted EBITDA loss of €42.7 million.
  • Management cited a significant deceleration in growth and profitability as the driver behind the revised full-year outlook.

Evotec SE (NASDAQ: EVO) issued a significant downward revision to its full-year 2026 financial outlook, now anticipating annual revenue in the range of €570 million to €610 million, alongside an adjusted EBITDA forecast ranging from a loss of €70 million to a loss of €105 million. The scale of this guidance cut represents a substantial reset of market expectations for the drug discovery and development services provider.

The revised guidance range accompanies preliminary first-half 2026 results that already showed clear signs of deteriorating performance, with first-half revenue of €300.1 million and an adjusted EBITDA loss of €42.7 million for the six-month period. Extrapolating the revised full-year range implies continued challenging conditions through the second half of the year, rather than an expectation of a near-term rebound.

Management specifically attributed the guidance revision to a significant deceleration in both growth and profitability, language suggesting the challenges facing the company are structural or industry-wide in nature rather than tied to a single isolated factor. For a contract research organization like Evotec, this kind of broad deceleration often reflects reduced R&D spending commitments or delayed project timelines among the biopharmaceutical clients the company serves.

The magnitude of the adjusted EBITDA loss range, spanning from €70 million to €105 million for the full year, represents a striking deterioration for a company of Evotec's scale, and the width of that range itself signals meaningful uncertainty in management's own visibility into the remainder of the year's performance.

This guidance cut arrives at a moment when investors across the broader biopharma services and outsourcing sector have been closely scrutinizing spending trends among pharmaceutical and biotech clients, and Evotec's specific commentary regarding a significant deceleration may prompt further scrutiny of comparable companies operating in the drug discovery and development services space.

With €465.6 million in liquidity providing some financial cushion, Evotec appears positioned to manage through this period of reduced profitability without an immediate financing crisis, though the scale of the guidance revision suggests the path back to the growth and profitability levels previously expected by the market may take considerable time to materialize.